We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts
News

RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts

RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts
News

RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RXi Pharmaceuticals Corporation has announced that it has licensed exclusive worldwide rights from the University of Massachusetts Medical School (UMMS) to certain technology for the oral delivery of RNAi therapeutics.

The technology was developed by Dr. Michael Czech, Professor and Chair, Program in Molecular Medicine at UMMS and an RXi founder, and Dr. Gary R. Ostroff, Professor of Molecular Medicine at UMMS and an RXi collaborator. Financial terms were not disclosed.

Going forward, management noted, RXi intends to work with pharmaceutical and biotechnology partners to advance the discovery and development of orally delivered rxRNA™ therapeutics for a host of inflammatory diseases.
Advertisement